Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors

被引:6
|
作者
Zeng, Li [1 ]
Ma, Gang [2 ,3 ]
Chen, Kai [1 ]
Zhou, Qiao [3 ,4 ]
机构
[1] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Dept Neurol, Chengdu, Peoples R China
[2] Chengdu Univ Tradit Chinese Med, Chengdu, Peoples R China
[3] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Dept Rheumatol & Immunol, Chengdu, Peoples R China
[4] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Clin Immunol Translat Med Key Lab Sichuan Prov, Chengdu, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
immune checkpoint inhibitor; rheumatic immune-related adverse event; bibliometric; research trends; VOSviewer; CiteSpace; INDUCED SARCOIDOSIS; TUMOR RESPONSE; IMMUNOTHERAPY; AUTOIMMUNITY; NIVOLUMAB; BLOCKADE; ANTIBODY; CTLA4;
D O I
10.3389/fimmu.2023.1242336
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Immune checkpoint inhibitors (ICIs) has emerged as a popular cancer treatment approach. However, non-specific activation of T cells by ICIs can lead to immune-related adverse events (irAEs), including specific rheumatic manifestations. The study aimed to explore the current trend of ICIs associated rheumatic irAEs and summarize the knowledge structure through bibliometric methods.Methods The Web of Science Core Collection database (WoSCC) was selected for retrieving literature on ICIs associated rheumatic irAEs. To evaluate contributions from different countries/regions, institutions, journals, and authors, bibliometric analysis software, including VOSviewer and CiteSpace, as well as bibliometric online platforms, were utilized to construct and visualize bibliometric networks. Through the systematic review of this knowledge domain, future research directions were determined.Results In This study, a total of 803 publications on ICIs-associated rheumatic irAEs were included for analysis. The distribution of these publications revealed two distinct growth phases: a stable phase between 2007 to 2015 followed by rapid growth from 2016 to 2020. The United States emerged as the top contributor in terms of publications, citations, and h-index, with the majority of leading institutions and funding agencies located there. Apart from government funding, pharmaceutical companies such as Bristol Myers Squibb and Merck Company also play a significant role in drug development and research. Analysis of keywords and citation bursts indicated that the initial burst was related to "monoclonal antibody," "anti-CLTA4 antibody," and "melanoma". This was followed by a rise in interest related to "sarcoidosis," "safety," "inflammatory arthritis," and "preexisting autoimmune."Conclusion This study summarized the global research trends concerning ICIs associated rheumatic irAEs. The findings can provide valuable insights into the current understanding of rheumatic irAEs, highlight the research trend and developments in the field. Future efforts should focus on developing classification criteria and guidelines, conducting prospective studies, investigating the mechanisms involved, and identifying biomarkers for prediction and monitoring of these events.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy
    King, G. T.
    Sharma, P.
    Davis, S. L.
    Jimeno, A.
    DRUGS OF TODAY, 2018, 54 (02) : 103 - 122
  • [32] Management of challenging immune-related gastrointestinal adverse events associated with immune checkpoint inhibitors
    Hamamoto, Yasuo
    Shin, Natalya
    Hoshino, Tomohiro
    Kanai, Takanori
    FUTURE ONCOLOGY, 2018, 14 (30) : 3187 - 3198
  • [33] Cutaneous adverse events associated with immune checkpoint inhibitors
    Graen, Franziska
    Schilling, Bastian
    AKTUELLE DERMATOLOGIE, 2023, 49 (11) : 517 - 524
  • [34] Neurological immune-related adverse events associated with immune checkpoint inhibitors: A review of the literature
    Fan, Siyuan
    Ren, Haitao
    Zhao, Luo
    Yin, Jian
    Feng, Guodong
    Wang, Jiawei
    Guan, Hongzhi
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 (06) : 291 - 298
  • [35] RISK FACTORS FOR DEVELOPING RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS AFTER IMMUNOTHERAPY WITH IMMUNE CHECKPOINT INHIBITORS
    Liapi, M.
    Chatzidionysiou, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 2053 - 2054
  • [36] Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors
    Graen, Franziska
    Schilling, Bastian
    AKTUELLE RHEUMATOLOGIE, 2022, 47 (04) : 344 - 352
  • [37] Biomarkers for adverse events associated with immune checkpoint inhibitors
    Kourie, Hampig Raphael
    Paesmans, Marianne
    Klastersky, Jean
    BIOMARKERS IN MEDICINE, 2016, 10 (10) : 1029 - 1031
  • [38] Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature
    Cappelli, Laura C.
    Gutierrez, Anna Kristina
    Bingham, Clifton O., III
    Shah, Ami A.
    ARTHRITIS CARE & RESEARCH, 2017, 69 (11) : 1751 - 1763
  • [39] Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Literature Review
    Cappelli, Laura
    Gutierrez, Anna Kristina
    Shah, Ami A.
    Bingham, Clifton, III
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [40] Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer
    Zhou, Lin
    Wei, Xin
    FRONTIERS IN IMMUNOLOGY, 2021, 12